Dihydroartemisinin for metabolic fatty liver disease
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests whether dihydroartemisinin, a malaria drug that may reduce liver fat, helps people with metabolic fatty liver disease. It is for adults aged 18 to 45 who have a fatty liver and at least one metabolic problem like overweight, high blood pressure, or diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You have a fatty liver, shown by an ultrasound, CT scan, MRI, or a special test called FibroScan.
- You have at least one metabolic condition, such as overweight (BMI >= 24), high blood pressure, pre-diabetes or diabetes, high triglycerides, or low 'good' cholesterol.
- Your weight has been stable (no more than 5% change) in the last 3 months.
- You are not taking medications that can cause fatty liver (like steroids or certain other drugs) for more than 2 weeks in the past year.
- You do not drink too much alcohol (no more than 2 drinks per day for men, 1 for women).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a digital health app designed to help people with metabolic-associated fatty liver disease (MAFLD). The app provides diet and exercise guidance to improve liver health.
This trial tests whether diacerein can help people with metabolic dysfunction-associated fatty liver disease (MASLD). It may reduce liver fat and improve liver health. If you have this condition, this study may offer a new treatment option.
This study tests whether a diabetes medicine called henagliflozin can reduce liver scarring in people who have both fatty liver disease (MASLD) and type 2 diabetes. If you qualify, you may receive the study drug and help researchers learn if it can improve liver health.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This trial tests a traditional Chinese herbal capsule called Linzhi Jianghuang Fufang Huoxue Anshen. It aims to see if it can reduce fat in the liver and improve health in people with non-alcoholic fatty liver disease who also have conditions like high blood sugar, blood pressure, or cholesterol.
This study tests if a medicine called dihydroartemisinin (a type of artemisinin, often used for malaria) can help treat acne when applied to the skin. It's a small early-phase trial for people with acne vulgaris.
Hear when a new MAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.